Agile Therapeutics, Inc.
AGRX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $6 | $6 | $4 | $7 |
| % Growth | -2.4% | 58.2% | -45.8% | – |
| Cost of Goods Sold | $1 | $2 | $2 | $2 |
| Gross Profit | $4 | $4 | $1 | $4 |
| % Margin | 73.2% | 70.6% | 39.4% | 62.8% |
| R&D Expenses | $1 | $0 | $0 | $1 |
| G&A Expenses | $3 | $3 | $2 | $3 |
| SG&A Expenses | $6 | $6 | $5 | $7 |
| Sales & Mktg Exp. | $4 | $4 | $4 | $5 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $7 | $5 | $8 |
| Operating Income | -$3 | -$3 | -$4 | -$4 |
| % Margin | -49.2% | -48.2% | -112.1% | -60% |
| Other Income/Exp. Net | -$9 | $4 | -$0 | $3 |
| Pre-Tax Income | -$12 | $1 | -$4 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12 | $1 | -$4 | -$1 |
| % Margin | -212.9% | 22.5% | -123.7% | -12% |
| EPS | -1.73 | 0.28 | -1.51 | -0.27 |
| % Growth | -717.9% | 118.5% | -459.3% | – |
| EPS Diluted | -1.73 | 0.28 | -1.51 | -0.27 |
| Weighted Avg Shares Out | 7 | 5 | 3 | 3 |
| Weighted Avg Shares Out Dil | 7 | 5 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | $2 | -$4 | -$0 |
| % Margin | -49.2% | 27.5% | -112.5% | -5.4% |